Detection of circ-METRN expression levels in serum SEVs of patients with glioma early in radiation therapy not only helps to predict radioresistance and prognosis but also assists in the early detection of glioblastoma recurrence by MRI [103]. The gene discussed is METRN; the disease is glioblastoma.